Activation of classical (IL-6/IL-6R) or trans signaling (IL-6/sIL6R) occurs via gp130 and contributes to the sequestration of excess IL-6; blocking trans-signaling is effective in preclinical chronic and autoimmune diseases [45]. This evidence concerns the gene IL6 and autoimmune disease.